Information Provided By: 
Fly News Breaks for May 14, 2018
NKTR
May 14, 2018 | 08:37 EDT
H.C. Wainwright analyst Debjit Chattopadhyay said ASCO abstracts featuring data from Nektar's ongoing PIVOT-02 study have potentially reset expectations, but he also noted that the actual podium presentation is likely to include an updated cut of data from up to late May. The analyst, who thinks pullbacks in Nektar Therapeutics shares "could get compelling," maintains a Buy rating and $125 price target on the stock.
News For NKTR From the Last 2 Days
There are no results for your query NKTR
